Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
SUDEEPPHRM •NSE
Sudeep Pharma
₹1,156.4052.30 (4.74%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events
Performance
Today’s low
1,098.55
Today’s high
1,159.30
52 week low
524.05
52 week high
1,158.60
Open price
1,098.60
Previous close
1,104.10
Live volume
4,53,138
Lower circuit
1,048.90
Upper circuit
1,159.30
Fundamentals
Market Cap
₹12,438Cr
ROE
19.57%
P/E Ratio(TTM)
67.72
EPS(TTM)
16.26
P/B Ratio
14.08
Dividend Yield
0.00%
Industry P/E
38.10
Book Value
78.21
Debt to Equity
0.17
Face Value
1
Financial performance
JUN '26
Revenue (Cr)
₹164
-13.27%
Profit (Cr)
₹40.59
-16.38%
050100150200
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
| Revenue growth | Value |
|---|---|
| 1Y (TTM) | +26% |
| 3Y CAGR | +15% |
| Profit growth | Value |
|---|---|
| 1Y (TTM) | +30% |
| 3Y CAGR | +41% |
About
Sudeep Pharma Limited manufactures mineral-based value-added products for pharmaceutical, food, and nutraceutical industries.;
CEO/MD
Sujit Jaysukh Bhayani
Founded in
1989
NSE symbol
SUDEEPPHRM
Shareholding pattern
Mutual Funds Invested (4)
Similar stocks
| Stock | Mkt price (1D) | 52 week performance | Market cap | P/E ratio | P/B ratio | |
|---|---|---|---|---|---|---|
PfizerPFIZER | ₹4,919.50 +120.20 (2.50%) | 21,962.57 | 29.87 | 5.23 | ||
Caplin Point LaboratoriesCAPLIPOINT | ₹2,571.00 +41.30 (1.63%) | 19,232.10 | 28.36 | 5.36 | ||
Astrazeneca Pharma IndiaASTRAZEN | ₹7,500.50 -144.50 (1.89%) | 19,124.63 | 112.75 | 21.91 | ||
Natco PharmaNATCOPHARM | ₹886.85 -11.50 (1.28%) | 16,080.48 | 14.05 | 1.74 |
Livesquawk •
Sudeep Pharma projects asset turns for battery and greenfield facilities to range between 2.7 and 3.0.
The update was shared during the company's recent conference call.
Livesquawk •
Sudeep Pharma aims to meet FY27 targets via export, domestic expansion, and high-value products.
The company focuses on operational excellence to achieve its growth objectives.
Livesquawk •
Sudeep Pharma expects 30% PFN growth to sustain through FY28 post greenfield facility commissioning.
The company attributes Q1's 30% PFN growth to its ongoing facility expansion and operations.
Livesquawk •
Sudeep Pharma's NSS subsidiary targets gradual recovery with improved growth and profitability as European markets normalize.
The company aims for NSS to achieve similar margins as its core specialty ingredient business by FY'28.
Livesquawk •
Sudeep Pharma expects specialty ingredients to resume growth from Q2 after Q1 constraints.
The company faced temporary operational constraints in Q1, per concall update.
Livesquawk •
Sudeep Pharma aims to sustain EBITDA margins between 37-38% for the business.
The company reiterated its guidance during a recent concall update.
Livesquawk •
Sudeep Pharma expects Q1 FY'27 momentum to sustain into Q2, as per management.
Historically stronger H2 supports expectations for strong growth in FY'27, says Sudeep Pharma.
2026
4
Aug
Quarterly Result
Release date
23JulDividendEx date₹1.50per share
23
Jul
Dividend
Ex date
₹1.50
per share
For each share you hold, you will receive ₹1.50
Dividend amount₹1.50 per share
Dividend TypeFinal
Ex Date23 Jul ‘26
Record Date23 Jul ‘26
Announcement date21 May ‘26
21MayDividendAnnounced₹1.50per share
21
May
Dividend
Announced
₹1.50
per share
For each share you hold, you will receive ₹1.50
Dividend amount₹1.50 per share
Dividend TypeFinal
Ex Date23 Jul ‘26
Record Date23 Jul ‘26
Announcement date21 May ‘26
21
May
Quarterly & Annual Result
Release date
6
Feb
Quarterly Result
Release date
2025
19
Dec
Quarterly Result
Release date
Events calendar
View upcoming events in other stocks